JAHA:心力衰竭患者肝因子硒蛋白P水平升高与肝脏低灌注相关

2022-05-28 MedSci原创 MedSci原创

肝脏硒蛋白P水平与肝脏低灌注相关,其可能是一种参与心肝相互作用的新靶点,也是一种预测HF患者预后的生物标志物。

心脏和多器官网络本质上参与了心力衰竭的病理生理过程。非心血管合并症加速疾病进展,增加死亡风险。HF患者常合并有肝脏疾病,20%~30%的HF患者存在肝功能异常。HF导致肝脏持续低灌注和充血,并伴有肝脏损伤和肝细胞坏死。肝酶升高以及肝纤维化评分升高是HF患者预后不良的独立预测因素。心脏和肝脏之间的双向关系在HF的发生和发展中发挥重要作用,但它们在心脏和肝脏相互作用中的确切机制尚未完全阐明。

肝因子由肝脏合成和分泌,在外周组织中起调节作用。近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员的目的是明确肝因子硒蛋白P在HF患者中的临床意义。

这项前瞻性观察研究纳入了296名参与者,包含253名HF住院患者和43名对照者。首先,研究人员调查了受试者的硒蛋白P水平,发现HF患者的硒蛋白P水平明显高于对照者。

然后通过腹部超声检查,将HF患者分为肝脏充血和肝脏灌注不足4组。伴有肝灌注不足的HF患者硒蛋白P水平明显高于无肝灌注的患者,但伴有肝灌注和无肝灌注的患者硒蛋白P水平无显著差异。硒蛋白P水平与腹腔动脉收缩峰值速度呈负相关,而硒蛋白P水平与肝脏剪切波弹性成像无相关性。Kaplan‐Meier分析显示,高硒蛋白P水平的心衰患者与不良心脏结局增加(包括心脏死亡和心衰恶化)显著相关。

由此可见,肝脏硒蛋白P水平与肝脏低灌注相关,其可能是一种参与心肝相互作用的新靶点,也是一种预测HF患者预后的生物标志物。

 

原始出处:

Ryohei Takeishi.et al.Increases in Hepatokine Selenoprotein P Levels Are Associated With Hepatic Hypoperfusion and Predict Adverse Prognosis in Patients With Heart Failure.JAHA.2022.https://www.ahajournals.org/doi/10.1161/JAHA.121.024901

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2126642, encodeId=ce1c212664283, content=<a href='/topic/show?id=072c5088466' target=_blank style='color:#2F92EE;'>#心力衰竭#</a>患者肝因子<a href='/topic/show?id=c545e352216' target=_blank style='color:#2F92EE;'>#硒蛋白#</a>P水平升高与<a href='/topic/show?id=94f7105900d8' target=_blank style='color:#2F92EE;'>#肝脏低灌注#</a>相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50884, encryptionId=072c5088466, topicName=心力衰竭), TopicDto(id=73522, encryptionId=c545e352216, topicName=硒蛋白), TopicDto(id=105900, encryptionId=94f7105900d8, topicName=肝脏低灌注)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Tue Apr 18 07:43:05 CST 2023, time=2023-04-18, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2041726, encodeId=1f642041e2606, content=<a href='/topic/show?id=400ae352378' target=_blank style='color:#2F92EE;'>#硒蛋白P#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73523, encryptionId=400ae352378, topicName=硒蛋白P)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Apr 21 14:34:14 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223275, encodeId=6fc112232e5bb, content=学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e76499938, createdName=ms6000001791212108, createdTime=Mon May 30 01:02:39 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268837, encodeId=e8fe126883ee0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun May 29 23:34:14 CST 2022, time=2022-05-29, status=1, ipAttribution=)]
    2023-04-18 侠胆医心 来自香港

    #心力衰竭#患者肝因子#硒蛋白#P水平升高与#肝脏低灌注#相关

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2126642, encodeId=ce1c212664283, content=<a href='/topic/show?id=072c5088466' target=_blank style='color:#2F92EE;'>#心力衰竭#</a>患者肝因子<a href='/topic/show?id=c545e352216' target=_blank style='color:#2F92EE;'>#硒蛋白#</a>P水平升高与<a href='/topic/show?id=94f7105900d8' target=_blank style='color:#2F92EE;'>#肝脏低灌注#</a>相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50884, encryptionId=072c5088466, topicName=心力衰竭), TopicDto(id=73522, encryptionId=c545e352216, topicName=硒蛋白), TopicDto(id=105900, encryptionId=94f7105900d8, topicName=肝脏低灌注)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Tue Apr 18 07:43:05 CST 2023, time=2023-04-18, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2041726, encodeId=1f642041e2606, content=<a href='/topic/show?id=400ae352378' target=_blank style='color:#2F92EE;'>#硒蛋白P#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73523, encryptionId=400ae352378, topicName=硒蛋白P)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Apr 21 14:34:14 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223275, encodeId=6fc112232e5bb, content=学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e76499938, createdName=ms6000001791212108, createdTime=Mon May 30 01:02:39 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268837, encodeId=e8fe126883ee0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun May 29 23:34:14 CST 2022, time=2022-05-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2126642, encodeId=ce1c212664283, content=<a href='/topic/show?id=072c5088466' target=_blank style='color:#2F92EE;'>#心力衰竭#</a>患者肝因子<a href='/topic/show?id=c545e352216' target=_blank style='color:#2F92EE;'>#硒蛋白#</a>P水平升高与<a href='/topic/show?id=94f7105900d8' target=_blank style='color:#2F92EE;'>#肝脏低灌注#</a>相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50884, encryptionId=072c5088466, topicName=心力衰竭), TopicDto(id=73522, encryptionId=c545e352216, topicName=硒蛋白), TopicDto(id=105900, encryptionId=94f7105900d8, topicName=肝脏低灌注)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Tue Apr 18 07:43:05 CST 2023, time=2023-04-18, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2041726, encodeId=1f642041e2606, content=<a href='/topic/show?id=400ae352378' target=_blank style='color:#2F92EE;'>#硒蛋白P#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73523, encryptionId=400ae352378, topicName=硒蛋白P)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Apr 21 14:34:14 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223275, encodeId=6fc112232e5bb, content=学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e76499938, createdName=ms6000001791212108, createdTime=Mon May 30 01:02:39 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268837, encodeId=e8fe126883ee0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun May 29 23:34:14 CST 2022, time=2022-05-29, status=1, ipAttribution=)]
    2022-05-30 ms6000001791212108

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2126642, encodeId=ce1c212664283, content=<a href='/topic/show?id=072c5088466' target=_blank style='color:#2F92EE;'>#心力衰竭#</a>患者肝因子<a href='/topic/show?id=c545e352216' target=_blank style='color:#2F92EE;'>#硒蛋白#</a>P水平升高与<a href='/topic/show?id=94f7105900d8' target=_blank style='color:#2F92EE;'>#肝脏低灌注#</a>相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50884, encryptionId=072c5088466, topicName=心力衰竭), TopicDto(id=73522, encryptionId=c545e352216, topicName=硒蛋白), TopicDto(id=105900, encryptionId=94f7105900d8, topicName=肝脏低灌注)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Tue Apr 18 07:43:05 CST 2023, time=2023-04-18, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2041726, encodeId=1f642041e2606, content=<a href='/topic/show?id=400ae352378' target=_blank style='color:#2F92EE;'>#硒蛋白P#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73523, encryptionId=400ae352378, topicName=硒蛋白P)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Apr 21 14:34:14 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223275, encodeId=6fc112232e5bb, content=学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e76499938, createdName=ms6000001791212108, createdTime=Mon May 30 01:02:39 CST 2022, time=2022-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268837, encodeId=e8fe126883ee0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun May 29 23:34:14 CST 2022, time=2022-05-29, status=1, ipAttribution=)]
    2022-05-29 zhaohui6731

相关资讯

女性当“心”!长期不孕或增加心衰风险?

往期研究表明,生殖因素或许与心血管疾病风险的增加有关,但不孕与心力衰竭之间究竟存在怎样的关系?此种潜在联系值得我们一探究竟。

Circ-Heart Fail:急性心肌梗死和心力衰竭相关心源性休克的临床特征、住院病程和1年结局比较

HF-CS患者较年轻,尽管心功率输出较低,肺毛细血管楔形压较高,但接受血管加压药或临时机械循环支持的可能性较小。

PAH与PH-HFpEF如何区别

鉴于其对PAH治疗的积极反应,PH在HFpEF中的作用目前正受到密切关注,因为它约占HF患者的50%,对流行病学影响很大,而且缺乏有效管理。

阿斯利康表示Farxiga达到了III期心力衰竭研究的主要终点

一线结果显示,SGLT2抑制剂与心血管(CV)死亡或心力衰竭恶化的主要复合终点显著降低相关。

心衰治疗“金三角”,有哪些药?怎么用?

心衰药物治疗主要靠这七种“武器”。